Decreased Postnatal Docosahexaenoic and Arachidonic Acid Blood Levels in Premature Infants are Associated with Neonatal Morbidities - 11/10/11
Abstract |
Objective |
To measure the changes in whole blood fatty acid levels in premature infants and evaluate associations between these changes and neonatal morbidities.
Study design |
This was a retrospective cohort study of 88 infants born at <30 weeks’ gestation. Serial fatty acid profiles during the first postnatal month and infant outcomes, including chronic lung disease (CLD), retinopathy of prematurity, and late-onset sepsis, were analyzed. Regression modeling was applied to determine the association between fatty acid levels and neonatal morbidities.
Results |
Docosahexaenoic acid (DHA) and arachidonic acid levels declined rapidly in the first postnatal week, with a concomitant increase in linoleic acid levels. Decreased DHA level was associated with an increased risk of CLD (OR, 2.5; 95% CI, 1.3-5.0). Decreased arachidonic acid level was associated with an increased risk of late-onset sepsis (hazard ratio, 1.4; 95% CI, 1.1-1.7). The balance of fatty acids was also a predictor of CLD and late-onset sepsis. An increased linoleic acid:DHA ratio was associated with an increased risk of CLD (OR, 8.6; 95% CI, 1.4-53.1) and late-onset sepsis (hazard ratio, 4.6; 95% CI, 1.5-14.1).
Conclusion |
Altered postnatal fatty acid levels in premature infants are associated with an increased risk of CLD and late-onset sepsis.
Le texte complet de cet article est disponible en PDF.Mots-clés : AA, CLD, DHA, LA, LCPUFA, NEC, NICU, ROP
Plan
Supported by the Program for Faculty Development and Diversity of Harvard Catalyst, Harvard Clinical and Translational Science Center, National Center for Research Resources (award UL1 RR 025758 and financial contributions from Harvard University and its affiliated academic health care centers), the Charles H. Hood Foundation, the Alden Trust, and the Gerber Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, the National Center for Research Resources, or the National Institutes of Health. None of the funding bodies had any role in the study design or conduct; data collection, management, analysis or interpretation; or manuscript preparation, review, or approval. The authors declare no conflicts of interest. |
Vol 159 - N° 5
P. 743 - novembre 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?